Type I IFN-mediated regulation of IL-1 production in inflammatory disorders

Although contributing to inflammatory responses and to the development of certain autoimmune pathologies, type I interferons (IFNs) are used for the treatment of viral, malignant, and even inflammatory diseases. Interleukin-1 (IL-1) is a strongly pyrogenic cytokine and its importance in the developm...

Full description

Saved in:
Bibliographic Details
Published in:Cellular and molecular life sciences : CMLS 2012-10, Vol.69 (20), p.3395-3418
Main Authors: Ludigs, Kristina, Parfenov, Valeriy, Du Pasquier, Renaud A, Guarda, Greta
Format: Article
Language:English
Subjects:
Animals
Autoimmune diseases
Biochemistry
Biomedical and Life Sciences
Biomedicine
Cell Biology
diseases
disorders
Humans
inflammation
Inflammation - drug therapy
Inflammation - metabolism
Inflammatory diseases
Interferon Type I - therapeutic use
interferons
interleukin-1
Interleukin-1 - metabolism
Life Sciences
Medical disorders
Review
sclerosis
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although contributing to inflammatory responses and to the development of certain autoimmune pathologies, type I interferons (IFNs) are used for the treatment of viral, malignant, and even inflammatory diseases. Interleukin-1 (IL-1) is a strongly pyrogenic cytokine and its importance in the development of several inflammatory diseases is clearly established. While the therapeutic use of IL-1 blocking agents is particularly successful in the treatment of innate-driven inflammatory disorders, IFN treatment has mostly been appreciated in the management of multiple sclerosis. Interestingly, type I IFNs exert multifaceted immunomodulatory effects, including the reduction of IL-1 production, an outcome that could contribute to its efficacy in the treatment of inflammatory diseases. In this review, we summarize the current knowledge on IL-1 and IFN effects in different inflammatory disorders, the influence of IFNs on IL-1 production, and discuss possible therapeutic avenues based on these observations.
ISSN:1420-682X
1420-9071
DOI:10.1007/s00018-012-0989-2